241 related articles for article (PubMed ID: 32193333)
1. 5-Aza-2'-deoxycytidine advances the epithelial-mesenchymal transition of breast cancer cells by demethylating
Lu A; Wang W; Wang-Renault SF; Ring BZ; Tanaka Y; Weng J; Su L
J Cell Sci; 2020 May; 133(9):. PubMed ID: 32193333
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
3. Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.
Tao J; Liu Q; Wu X; Xu X; Zhang Y; Wang Q; Luo C
Int J Med Sci; 2013; 10(13):1860-7. PubMed ID: 24324362
[TBL] [Abstract][Full Text] [Related]
4. DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells.
Xiang T; Fan Y; Li C; Li L; Ying Y; Mu J; Peng W; Feng Y; Oberst M; Kelly K; Ren G; Tao Q
Oncotarget; 2016 Oct; 7(43):70924-70935. PubMed ID: 27708215
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
6. The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of
Dudzik P; Trojan SE; Ostrowska B; Zemanek G; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Anticancer Res; 2019 May; 39(5):2395-2403. PubMed ID: 31092432
[TBL] [Abstract][Full Text] [Related]
7. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
8. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
[TBL] [Abstract][Full Text] [Related]
9. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
10. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
Manjegowda MC; Gupta PS; Limaye AM
Gene; 2017 May; 614():65-73. PubMed ID: 28286086
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation as a novel regulator of ANO1 expression and function in prostate cancer bone metastasis.
Shin Y; Kim S; An W
Sci Rep; 2024 May; 14(1):11595. PubMed ID: 38773164
[TBL] [Abstract][Full Text] [Related]
12. Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells.
Muñoz DP; Lee EL; Takayama S; Coppé JP; Heo SJ; Boffelli D; Di Noia JM; Martin DI
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2977-86. PubMed ID: 23882083
[TBL] [Abstract][Full Text] [Related]
13. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Hartsough MT; Clare SE; Mair M; Elkahloun AG; Sgroi D; Osborne CK; Clark G; Steeg PS
Cancer Res; 2001 Mar; 61(5):2320-7. PubMed ID: 11280805
[TBL] [Abstract][Full Text] [Related]
14. Aberrant promoter methylation may be responsible for the control of CD146 (MCAM) gene expression during breast cancer progression.
Dudzik P; Trojan SE; Ostrowska B; Lasota M; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Acta Biochim Pol; 2019 Dec; 66(4):619-625. PubMed ID: 31826047
[TBL] [Abstract][Full Text] [Related]
15. [The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
Tang B; Peng ZH; Jiang J
Zhonghua Wai Ke Za Zhi; 2005 Dec; 43(23):1545-9. PubMed ID: 16412295
[TBL] [Abstract][Full Text] [Related]
16. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG; Jones WD; Coleman WB
Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
[TBL] [Abstract][Full Text] [Related]
18. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
[TBL] [Abstract][Full Text] [Related]
20. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
